OraSure Technologies Independent Director Acquires 195% More Stock
OraSure Technologies (NASDAQ:OSUR) Independent Director, Steven Boyd, recently purchased US$225k worth of the company's stock at US$3.00 per share, increasing his holding by 195%. This significant insider purchase suggests optimism despite the company not making a profit in the last year. The article highlights that insiders owning 6.1% of the company indicates a reasonable degree of alignment with shareholders and a potential belief that the share price is undervalued.
OraSure Technologies (OSUR) price target increased by 25.00% to 5.10
The article reports that the price target for OraSure Technologies (OSUR) has been increased by 25% to $5.10. This indicates a revised outlook for the company's stock by analysts.
OraSure director Steven Boyd purchases $224,750 in stock
OraSure Technologies Inc. director Steven Boyd recently acquired 75,000 shares of the company's common stock over three days, totaling $224,750. These purchases, made at prices between $2.98 and $3.02 per share, increased his direct ownership to 113,462 shares. The transactions occurred after OraSure's stock gained 28% in six months, despite a recent Q1 2026 earnings and revenue miss.
OraSure (OSUR) director has 21,305 shares withheld to cover tax on vested stock
OraSure Technologies director Nancy J. Gagliano reported a tax-related share disposition. On May 13, 2026, 21,305 shares of common stock were withheld at $3.02 per share to cover tax liabilities associated with the vesting of restricted shares. After this transaction, Ms. Gagliano directly holds 138,949 OraSure common shares.
Insider Buying: Steven Boyd Acquires 75,000 Shares of OraSure Te
Steven Boyd, a Director at OraSure Technologies Inc (OSUR), recently purchased 75,000 shares, increasing his total holdings to 113,462 shares. This transaction is part of a trend of six insider buys and no insider sells over the past year, indicating positive insider sentiment. Despite the insider confidence, the stock is currently trading at $3 per share, significantly above its GF Value estimate of $1.95, suggesting it is overvalued.
OraSure director Steven Boyd purchases $224,750 in stock
OraSure Technologies Inc. director Steven Boyd recently purchased 75,000 shares of the company's common stock for a total of $224,750. These purchases occurred between May 12 and May 14, 2026, with prices ranging from $2.98 to $3.02 per share, bringing his total direct ownership to 113,462 shares. This activity follows OraSure's Q1 2026 results, which missed EPS and revenue expectations.
[Form 3] ORASURE TECHNOLOGIES INC Initial Statement of Beneficial Ownership
OraSure Technologies director John D. Bertrand has filed a Form 3, which is an initial statement of beneficial ownership. This filing is administrative and indicates no share purchases, sales, or option exercises by Bertrand. Investors use Form 3 to track initial equity holdings of new company insiders.
Director at OraSure (NASDAQ: OSUR) awarded 33,661 restricted shares
OraSure Technologies director John D. Bertrand received a grant of 33,661 restricted shares of common stock as an equity award without cash cost. These shares will cliff vest on May 12, 2028, provided he continues to serve on the Board, otherwise, vesting will cease. This transaction was reported in a Form 4 filing and increases his direct holdings to 33,661 common shares.
OraSure Technologies (OSUR) director buys 75,000 shares in market trades
OraSure Technologies Inc. director Steven Kyle Boyd purchased a total of 75,000 shares of the company's Common Stock in open-market transactions over three days, with prices ranging from $2.98 to $3.02 per share. Following these transactions, Mr. Boyd directly owns 113,462 shares. This insider buying activity is considered a positive sentiment for the company.
OraSure Technologies stock (US68880C1018): Recent price action and trading update
OraSure Technologies (OSUR) shares recently rose 2.4% to $3.04, reflecting investor interest in the diagnostics firm. The company specializes in oral fluid diagnostic products and specimen collection devices for infectious diseases and substance abuse. Its Nasdaq listing and focus on public health initiatives make it relevant for US investors.
OraSure Technologies stock (US68880C1018): Core business and market position
OraSure Technologies (OSUR) specializes in rapid diagnostic tests for infectious diseases and substance abuse, emphasizing point-of-care solutions with significant US market exposure. The company's core products include OraQuick for HIV testing and molecular collection devices, which drove a 5% year-over-year revenue increase to $53.2 million in Q4 2025. OraSure benefits from the growing demand for rapid, non-invasive diagnostics and its focus on affordable, accessible tests, making it a key player in the US public health infrastructure.
OraSure anticipates Q2 revenue of $27M-$30M as it targets midyear FDA clearances for CT/NG and Colli-Pee
OraSure Technologies is projecting second-quarter revenue between $27 million and $30 million. The company is also actively pursuing midyear FDA clearance for its CT/NG assay and Colli-Pee urine collection device, which are key to its diagnostic portfolio expansion.
[10-Q] ORASURE TECHNOLOGIES INC Quarterly Earnings Report
OraSure Technologies Inc. (OSUR) has filed its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The report details a net loss of $22.377 million, or $0.32 per share, compared to a net loss of $16.040 million, or $0.21 per share, for the same period in 2025. Consolidated net revenues decreased by 7% to $27.9 million, primarily due to lower international HCV revenues and a significant drop in COVID-19 Diagnostics sales, partially offset by increased research and development expenses and a higher operating loss.
OraSure Technologies (OSUR) Loss Worsening In Q1 2026 Challenges Bullish Margin Narratives
OraSure Technologies (OSUR) reported a worsening loss in Q1 2026, with a basic EPS loss of US$0.32 and a net loss of US$22.4 million, despite similar revenue compared to the previous quarter. The company's financials challenge bullish narratives about future growth and margin stabilization, as losses have widened and revenue growth remains modest. Analysts predict continued unprofitability for the next three years, emphasizing the risks associated with product launches and market reliance.
OSUR SEC Filings - Orasure Tech 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to OraSure Technologies (OSUR) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside AI-powered summaries. Recent filings detail insider stock awards and tax withholdings for executives, a deeper loss in 2025 due to reduced COVID-related demand, and an activist campaign by Altai Capital Management seeking board changes. The company is actively managing costs and pursuing new product clearances to return to growth.
OraSure Technologies (OSUR) Reports Q1 2026 Revenue of $27.9 Mil
OraSure Technologies (OSUR) reported Q1 2026 revenue of $27.9 million, surpassing guidance, and achieved a gross margin of 42.3%. The company forecasts Q2 revenue between $27 million and $30 million. Insider buying activity suggests confidence, though profitability and growth remain areas for improvement given its GF Score™ of 67.
OraSure Technologies Reports Q1 2026 Financial Results
OraSure Technologies exceeded its Q1 2026 revenue guidance with $27.9 million and achieved solid gross margin expansion. CEO Carrie Eglinton Manner highlighted the company's strategic transformation, focusing on optimizing manufacturing, diversifying its product portfolio, and accelerating growth through R&D and strategic partnerships. OraSure is also preparing for two significant product launches mid-year: a rapid molecular self-test for chlamydia and gonorrhea, and the COLI P at-home urine collection device for STIs.
OraSure anticipates Q2 revenue of $27M-$30M as it targets midyear FDA clearances for CT/NG and Colli-Pee
OraSure Technologies is projecting second-quarter revenue between $27 million and $30 million. The company is seeking midyear FDA clearances for its CT/NG and Colli-Pee testing products, which could significantly impact its future performance. These clearances are key to its growth strategy in the diagnostics market.
OraSure Technologies Inc reports results for the quarter ended December 31 - Earnings Summary
OraSure Technologies Inc has released its earnings summary for the quarter that concluded on December 31. The report, provided by Refinitiv, gives an overview of the company's financial performance during this period. The news item is concise, indicating it's a brief update on the financial results.
OraSure: Q1 Earnings Snapshot
OraSure Technologies Inc. (OSUR) reported a first-quarter loss of $22.4 million, translating to a loss of 32 cents per share. Adjusted for one-time costs, the loss was 24 cents per share. The diagnostic test maker also announced quarterly revenue of $27.9 million.
Earnings call transcript: OraSure Technologies Q1 2026 misses earnings and revenue forecasts
OraSure Technologies reported a disappointing Q1 2026, missing both earnings per share (EPS) and revenue forecasts with an EPS of -$0.24 against an anticipated -$0.20 and revenue of $27.9 million versus a forecasted $28.6 million. Despite these misses, the company's stock price remained stable at $3 in aftermarket trading, suggesting investor anticipation or focus on future developments. The company highlighted operational efficiencies leading to improved gross margins and is looking forward to upcoming product launches, including a rapid molecular self-test for chlamydia and gonorrhea and the Colli-Pee at-home urine collection device, expected to receive FDA clearance by mid-2026 and drive second-half revenue growth.
OraSure Technologies Q1 Earnings Call Highlights
OraSure Technologies reported Q1 2026 revenue of $27.9 million, a 4% sequential increase, driven by a 12% rise in diagnostics revenue. The company improved GAAP gross margins to 42.3% and anticipates similar margins in Q2 while awaiting FDA review for two new product launches: an OTC rapid molecular CT/NG self-test and the Colli-Pee at-home urine collection device, which are expected to contribute revenue in the latter half of 2026. Despite a Q1 GAAP operating loss of $23.3 million, OraSure maintains a strong cash position of $177 million with no debt and expects to return to break-even operating cash flow by early 2027.
OraSure Technologies (NASDAQ:OSUR) Announces Quarterly Earnings Results, Misses Estimates By $0.08 EPS
OraSure Technologies (NASDAQ:OSUR) announced its quarterly earnings, reporting an EPS of ($0.24), missing consensus estimates by $0.08. Despite a GAAP operating loss of $23.3 million, the company achieved $27.9 million in revenue and expanded non-GAAP gross margin to 43.4% due to insourcing. Management anticipates FDA clearances and commercial launches for its CT/NG rapid molecular OTC self-test and Colli-Pee in mid-2026, targeting revenue growth in the second half of the year, and aims for break-even operating cash flow by 2027.
OraSure: Q1 Earnings Snapshot
OraSure Technologies Inc. (OSUR) reported a first-quarter loss of $22.4 million, translating to 32 cents per share. Adjusted for certain expenses, the loss was 24 cents per share. The diagnostic test manufacturer also announced revenues of $27.9 million for the period.
OraSure: Q1 Earnings Snapshot
OraSure Technologies Inc. (OSUR) reported a net loss of $22.4 million in its first quarter, translating to a loss of 32 cents per share. Adjusted losses were 24 cents per share. The diagnostic test maker also announced revenues of $27.9 million for the period.
OraSure (NASDAQ: OSUR) posts Q1 2026 revenue drop and wider net loss
OraSure Technologies (NASDAQ: OSUR) reported a revenue decrease and wider net loss for Q1 2026, with net revenues falling 7% year-over-year to $27.9 million and GAAP net loss widening to $22.4 million. Despite improved gross margins due to cost controls, operating expenses weighed on profitability. The company currently holds $177 million in cash and cash equivalents and has guided Q2 2026 revenues to be between $27–$30 million, expecting stable non-GAAP gross margins.
OraSure Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
OraSure Technologies, Inc. has released its earnings report for the first quarter ended March 31, 2026. The company reported a decrease in sales to $27.93 million from $29.93 million a year ago. Consequently, the net loss significantly widened to $22.38 million, compared to $16.04 million in the prior year, resulting in a higher basic and diluted loss per share from continuing operations.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) is scheduled to announce its first quarter 2026 financial results on Monday, May 6th, after the market closes. The company will also host a conference call and webcast to discuss these results on the same day at 5:00 p.m. ET. Investors and interested parties can access the live webcast or listen to a replay through the company's website.
OraSure Technologies Inc expected to post a loss of 23 cents a share - Earnings Preview
OraSure Technologies Inc (OSUR) is projected to report a loss of 23 cents per share. This information is provided as an earnings preview by Refinitiv. The article is very brief, offering only this financial expectation.
Vanguard discloses 3.48M-share stake in OraSure (NASDAQ: OSUR)
Vanguard Capital Management has disclosed beneficial ownership of 3,484,438 shares of OraSure Technologies Inc (NASDAQ: OSUR) common stock, representing 5.04% of the class. This Schedule 13G filing indicates Vanguard has sole voting power over 453,550 shares and sole dispositive power over all 3,484,438 shares. The filing clarifies that these holdings include securities managed for Vanguard funds and affiliated entities.
OraSure Technologies (OSUR) Projected to Post Quarterly Earnings on Wednesday
OraSure Technologies (NASDAQ:OSUR) is anticipated to release its Q1 2026 earnings after the market closes on Wednesday, May 6th, with analysts projecting a loss of ($0.16) per share and revenue of $27.6740 million. The company recently reported Q4 earnings of ($0.19) per share, missing consensus estimates, and disclosed recent insider stock purchases by its CFO and CEO. Hedge funds and institutional investors have adjusted their stakes, while analysts currently hold a "Reduce" rating with an average target price of $3.00 for the stock.
Activist Altai Capital pushes for OraSure sale, board seats (update)
Activist investor Altai Capital is pressuring OraSure Technologies to sell itself and accept nominations for its board. Altai, which owns a significant stake in OraSure, believes the company's valuation is too low and that a sale could unlock greater shareholder value.
Peapod Lane Capital LLC Has $2.47 Million Position in OraSure Technologies, Inc. $OSUR
Peapod Lane Capital LLC significantly increased its stake in OraSure Technologies, making it their 17th-largest holding. Meanwhile, insider activity shows the CEO and CFO recently purchased shares, indicating confidence in the company. Despite this, OraSure Technologies is currently trading near $3.05 with a "Reduce" analyst consensus and a target price of $3.00, having reported negative EPS and margins last quarter.
OSUR SEC Filings - Orasure Tech 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to OraSure Technologies (OSUR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms, enhanced with AI-powered summaries and sentiment analysis. Recent filings reveal activist investor Altai Capital building a significant stake to push for strategic review and board changes, while the company's Q4 2025 results show a deep loss and revenue decline due to fading COVID-19 demand, offset by cost actions and new product aspirations. Insider transaction details for the CEO and CFO are also highlighted, alongside a director's resignation.
OSUR SEC Filings - Orasure Tech 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for OraSure Technologies (OSUR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. It features AI-powered summaries and real-time updates from EDGAR to help investors quickly analyze the company's financial performance, governance changes, and material disclosures. Recent filings cover quarterly financial results, changes in the board of directors, and insider stock transactions related to tax withholding.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) will report its first quarter 2026 financial results and host an earnings conference call on May 6, 2026, at 5 p.m. ET. A webcast of the call will be available on the company's investor relations website, where it will also be archived. OraSure specializes in diagnostic tests and sample collection solutions, improving access and quality in healthcare.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) has announced it will report its first quarter 2026 financial results and host an earnings conference call on May 6, 2026, at 5 p.m. ET. A webcast of the call will be accessible on the investor relations page of OraSure’s website. The company transforms health through actionable insights and develops rapid diagnostic tests and sample collection devices globally.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will release its first quarter 2026 financial results and host an earnings conference call on May 6, 2026, at 5 p.m. ET. A webcast of the call will be available on the investor relations section of the company's website. OraSure specializes in diagnostic tests and sample collection solutions, aiming to transform health through actionable insights and decentralized diagnostics.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) is scheduled to announce its first-quarter 2026 financial results and business developments during an earnings conference call on May 6, 2026, at 5 p.m. ET. A webcast of the call will be available on the investor relations page of OraSure's website. The company specializes in rapid diagnostic tests and sample collection solutions, transforming health through actionable insights.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) will announce its first quarter 2026 financial results during an earnings conference call on May 6, 2026, at 5 p.m. ET. A webcast of the call will be available on the company's investor relations website. OraSure develops and manufactures rapid diagnostic tests and sample collection devices globally.
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
OraSure Technologies, Inc. (NASDAQ: OSUR) announced it will release its first quarter 2026 financial results during a conference call on May 6, 2026, at 5 p.m. ET. The call will also cover certain business developments. The stock was trading at $3.12, down 1.27% in aftermarket hours on April 22, 2026.
OraSure (NASDAQ: OSUR) seeks vote to add 5M shares to equity plan, declassify board
OraSure Technologies is holding its 2026 Annual Meeting on June 3, 2026, where shareholders will vote on electing directors, ratifying Grant Thornton LLP as auditor, approving executive compensation, increasing the Stock Award Plan by 5 million shares, and declassifying the Board over three years. For 2025, the company reported $115 million in net revenue and achieved $19 million in annualized run-rate cost savings, ending the year with $199 million in cash and no debt. Shareholder engagement has influenced governance changes, including the proposed board declassification and adjustments to executive compensation structures to align with performance metrics.
Altai Capital (NASDAQ: OSUR) wins OraSure board role and standstill deal
Altai Capital Management and OraSure Technologies have reached a cooperation agreement, granting Altai Capital a board seat for John Bertrand and committing OraSure to seek stockholder approval to declassify its board. Altai, which beneficially owns 5.2% of OraSure's common stock, has agreed to standstill provisions, including a cap on ownership at 9.9%. This agreement transitions the relationship from a potential proxy contest to structured engagement, with the agreement set to run until March 31, 2027.
OraSure gains after cooperation pact with activist, adds nominee to board
OraSure Technologies is experiencing gains after reaching a cooperation pact with an activist investor. As part of this agreement, the company is adding a new nominee to its board of directors.
OraSure gains after cooperation pact with activist, adds nominee to board
This article indicates that OraSure has gained after reaching a cooperation pact with an activist investor. As part of this agreement, a nominee has been added to the company's board. The article provides only the headline as content.
OraSure gains after cooperation pact with activist, adds nominee to board
OraSure Technologies (OSUR) saw a slight increase in its stock price after reaching a cooperation agreement with activist investor Altai Capital. As part of the pact, OraSure will add John D. Bertrand to its board, and Altai Capital will withdraw its director nominations for the upcoming annual meeting.
OraSure (OSUR) adds John Bertrand to board in Altai cooperation deal
OraSure Technologies has entered into a Cooperation Agreement with Altai Capital, resulting in Altai withdrawing its prior director nominations and stockholder proposal. As part of this agreement, OraSure appointed John D. Bertrand as an independent Class II director and plans to seek stockholder approval to declassify the Board at the 2026 annual meeting. Bertrand will receive an initial equity award of $100,000 in common stock, vesting over two years.
OraSure Technologies Adds AI Diagnostics Executive John D. Bertrand to Board, Reaches Governance Deal With Activist Investor Altai Capital
OraSure Technologies has appointed John D. Bertrand, an AI diagnostics executive, to its board of directors and reached a cooperation agreement with activist investor Altai Capital Management. This move is part of OraSure’s strategy to strengthen its board expertise in AI and commercial healthcare technology and advance its transformation strategy. The agreement with Altai Capital includes the withdrawal of their board nominations and ongoing discussions on strategic and operational matters.
OraSure Technologies, Inc. Appoints John D. Bertrand as Independent Director to Its Board, Effective April 16, 2026
OraSure Technologies, Inc. has announced the appointment of John D. Bertrand to its Board of Directors as an independent director, effective April 16, 2026. Mr. Bertrand brings over a decade of experience in healthcare technology, including co-founding Digital Diagnostics Inc. and holding senior leadership positions at Epic Systems Corporation. He also served as a Senior Advisor to Bain Capital and Executive in Residence at 8VC, focusing on AI applications in healthcare.
OraSure Technologies Enters into Cooperation Agreement with Altai Capital
OraSure Technologies, Inc. announced it has entered into a Cooperation Agreement with Altai Capital Management, L.P., following constructive engagement. As part of the agreement, John D. Bertrand has been appointed as an independent director to OraSure's Board. Altai Capital will withdraw its director nominations for the Annual Meeting, and company representatives will regularly meet with Altai to discuss financial and strategic matters.
